This Phase III study, called SYL1001_V, will involve more than 30 hospitals in the United States. It will evaluate the efficacy and safety of tivanisiran ophthalmic solution on the signs and symptoms of patients with dry eye disease associated with Sjögren’s Syndrome. The study has been approved by the FDA in 30 days and will […]
Category Archives: Corporate News
The company will present results of the HELIX clinical trial with tivanisirán for the treatment of Dry Eye Syndrome, in which an improvement in central corneal damage and results in patients with Sjögren’s Syndrome are demonstrated. Sylentis will also present data from the development of SYL1801 for the treatment and prevention of diseases of the […]
The HELIX trial has shown improvement (p=0.035) in the reduction of central corneal staining Data will be presented to the FDA and other regulatory authorities during the second quarter of 2019 to define the regulatory strategy The results of the HELIX trial will be presented at the Annual Congress of the Association for Research in […]
Sylentis has reached the target of recruiting patients for its Phase III trial “HELIX” for the treatment of the signs and symptoms of dry eye disease. We estimate that the results of the trial will be available in the first four months of 2019. Madrid, October 19th, 2018.- Sylentis, PharmaMar Group (MSE:PHM), has announced […]
Tivanisiran is under investigation in a Phase III clinical trial, HELIX, in more than 30 European hospitals and 300 patients to determine its efficacy in dry eye syndrome Madrid, October 19th, 2017.- Sylentis, a Pharmaceutical Company of PharmaMar Group (PHM:MSE), pioneer in the development of new compounds based on genetic silencing technology through RNA […]
Sylentis sponsors the 11th Annual meeting of the Oligonucleotide Therapeutics Society (OTS). The meeting will be held in Leiden (The Netherlands) 11-14th October, 2015. Oligonucleotide Therapeutics Society is an open, nonprofit forum to foster academia and industry-based research and development of oligonucleotide therapeutics. You can find more information about this event on the following webpage: http://www.oligotherapeutics.org/2015-annual-meeting/
CAMBRIDGE, Mass. & MADRID–(BUSINESS WIRE)–Nov. 16, 2011— Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Sylentis, S.A., a Spanish bio-pharmaceutical company devoted to the research and development of new therapies based on RNAi, announced today that Alnylam has granted Sylentis a non-exclusive option for a new target-specific InterfeRx™ license. This license would […]
Sylentis, a biopharmaceutical company in Grupo Zeltia (MC:ZEL) which is a pioneer in the research and development of new drugs based on gene silencing (interference RNA: RNAi) and one of the four companies in the world with RNAi-based products undergoing clinical trials, has been authorised as a pharmaceutical laboratory to manufacture research drugs by the […]
Find this publication at: Sylentis reviews present knowledge on RNA interference applications Lopez-Fraga, M. et al. Biodrugs. 2009; 23(5):305-32.
Español